News

A new clinical trial launched by the National Institutes of Health (NIH) is evaluating the impact of an extra dose of an approved or authorized COVID-19 vaccine in people with multiple sclerosis (MS) and other autoimmune diseases who did not properly respond to an original vaccine regimen. Approximately 600 people will…

Landos Biopharma has entered into a research partnership with Johns Hopkins University School of Medicine focused on advancing LABP-66 as a potential oral, once-daily therapy for multiple sclerosis (MS) and other disorders, the company announced. LABP-66 is a lab-made molecule that activates NLRX1, a receptor that is key in…

Most people with multiple sclerosis (MS) in the U.S. have health insurance, but many lack important other types of insurance, such as life insurance, short-term disability insurance, and long-term care insurance, according to an online survey of patients. Its findings suggest that MS patients who are likely to be…

Blocking a particular receptor protein of the BMP signaling pathway effectively promoted the maturation of myelin-producing cells and myelin repair in two mouse models of multiple sclerosis (MS), a study showed. Notably, these benefits, observed even after disease onset, took place in the presence of fibrinogen, a blood clotting…

As the federal election looms in Canada, a nation that has one of the world’s highest rates of multiple sclerosis (MS), the MS Society of Canada is urging patients and advocates to inform candidates about issues of importance to the MS community. The letter-writing and social media campaign,…

People newly diagnosed with clinically isolated syndrome (CIS) or multiple sclerosis (MS) frequently experience pain, fatigue, depression, and anxiety in the first year after diagnosis, a new study finds. Fatigue was reported by almost two-thirds of new patients, and half experienced pain. Many individuals experienced multiple symptoms simultaneously,…

The Multiple Sclerosis Association of America (MSAA) is inviting people to participate in its Improving Lives Through Art Series, a cycle of virtual fundraising events starting Sept. 14. The kick-off event of this four-part fall series is a virtual follow-along painting experience. Tickets can be purchased here…

Ocrevus (ocrelizumab) reduces relapse risk and slows disability progression in multiple sclerosis (MS) but also is associated with higher hospitalization rates in older people with relapsing forms of the disease, a new observational study reports. Hospitalizations — which occurred mainly due to urinary tract infections — were more frequent…

D.C. United and its official sponsor, Leidos, opened a campaign to donate up to $20,000 to the National Multiple Sclerosis (MS) Society, the soccer team announced. The initiative aims to support the almost one million people in the U.S. living with multiple sclerosis (MS). Among them is…

A new research project, funded by the National Institutes of Health (NIH), aims to better understand how different types of cells in the nervous system — specifically neurons and glia cells — communicate with each other and ultimately affect both motor and non-motor functions. Its findings may have important implications…

The National Multiple Sclerosis Society will host the second edition of its Black MS Experience Summit, a virtual event to help forge connections among those who understand the experience of living with multiple sclerosis (MS) as a Black person. Register here to join the interactive, two-day…

NervGen Pharma announced that its Phase 1 clinical trial evaluating the safety and pharmacological properties of NVG-291 — its lead therapeutic candidate for multiple sclerosis (MS) and other neurologic conditions — in healthy volunteers is going according to plan, with early top-line data expected later this year. “The…

A variation in a gene called STK11, previously shown to increase the risk for multiple sclerosis (MS) among Caucasians, is now also linked to a greater likelihood of MS in Black people. In fact, the variation was significantly more common in Black MS patients with secondary progressive MS (SPMS),…

Sativex (nabiximols), a cannabis-based oral spray approved in the U.K. to ease spasticity — or muscle stiffness and spasms — in adults with multiple sclerosis (MS), remains unavailable to many patients there, according to a report by the MS Society UK. Sativex is the only licensed…

PoNS, a non-invasive devise to accompany physical therapy in multiple sclerosis (MS) patients with difficulty walking, will be available on the U.S. market early next year, its developer, Helius Medical Technologies, announced in a quarterly financial update. Short for Portable Neuromodulation Stimulator, the PoNS…

A smartphone-based app called Floodlight can reliably assess cognition, arm and hand function, and walking abilities in people with multiple sclerosis (MS), according to new analyses. “Detection of progression onset or worsening is critical to optimally adapt the therapeutic strategy” patients are using to treat the neurodegenerative disease,…

MediciNova is planning to launch a Phase 3 clinical trial that will evaluate its investigational oral candidate ibudilast (MN-166) in people with secondary progressive multiple sclerosis (SPMS) without relapses. The company is actively engaging with potential partners that could help fund the study. “Over the past quarter, we…

Cytocom has joined forces with La Jolla Institute for Immunology (LJI) to discover and develop new immune-modulating therapies targeting toll-like receptors (TLRs) for autoimmune diseases such as multiple sclerosis (MS), cancer, and infectious and chronic inflammatory conditions. TLRs are an important family of protein receptors found at the surface…

A Phase 3 clinical trial testing the effect of Ocrevus (ocrelizumab) on upper limb disability progression in people with primary progressive multiple sclerosis (PPMS) is recruiting participants. The trial, called O’HAND (NCT04035005), expects to enroll approximately 1,000 adults with PPMS, ages 18 to 65, at more than…

Probiotic supplements could ease disability, lessen depression, and improve overall health in people with relapsing-remitting multiple sclerosis (MS), according to an analysis of four randomized clinical trials. Physicians working with these patients might recommend “confirmed probiotic supplements” to help manage “MS concerns,” its scientists wrote, while noting that studies…

Ocrevus (ocrelizumab) safely and effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who responded poorly to other disease-modifying therapies (DMTs), final two-year data from the CHORDS Phase 3b clinical trial show. Notably, these benefits also were observed among patients who enrolled in the study…

Personal Zen, a digital anxiety management tool developed by Wise Therapeutics, eased anxiety and broad negative moods in people with pediatric-onset multiple sclerosis (MS), according to the results of a pilot study. This app-based therapy, a “mobile gamified version” of what is known as attention bias modification…

Lemtrada (alemtuzumab) does not have a substantial effect on blood pressure or platelet counts, and does not lead to bleeding in the brain of multiple sclerosis (MS) patients, according to a small Belgian study. The findings contrast with previous studies showing an increase in blood pressure, stroke, and…

Visits to the hospital related to multiple sclerosis (MS) are more common when it’s hot or when temperatures are more variable, but less likely to be needed when it’s humid, a new analysis suggests. The results were published in the International Journal of Environmental Research and Public Health, in…

MS Australia is again teaming up with Jean Hailes‘ Women’s Health Week, to promote good health for all women and girls and to support the multiple sclerosis (MS) community. About three times more women than men are affected by MS. “We are pleased to again be partnering…

People with multiple sclerosis (MS) who experienced relapses in the previous year are more likely to have better adherence to their current treatment regimen, a cross-sectional study reports. The research also identified associations between treatment adherence and a lower body mass index (BMI), and between better perceived mental health…

Meeting people and dating is challenging for people with multiple sclerosis (MS), but the experience of dating is highly personal and influenced by past experiences and beliefs, a small study reveals. The study, “Dating with a Diagnosis: The Lived Experience of People with Multiple Sclerosis,” was published in…

More than half of people with multiple sclerosis (MS) who require an informal caregiver have experienced abuse or mistreatment by that caregiver, according to a study conducted in California. The study, “Validity and Reliability of the Scale to Report Emotional Stress Signs–Multiple Sclerosis (STRESS-MS) in Assessing…

A nurse and PhD candidate with multiple sclerosis (MS) is looking for disease biomarkers that can help healthcare providers better estimate how individual cases of MS will progress. The goal of Stephanie Buxhoeveden’s research, now supported by a grant from the American Association of Nurse Practitioners (AANP), is…

Jazz Pharmaceuticals is planning to open a third Phase 3 clinical trial of Sativex (nabiximols), an oral spray that contains cannabis extracts, as an add-on treatment for people with multiple sclerosis (MS) and spasticity, the company announced. Set to start this year, the RELEASE MSS5…